Market Survey on Parkinson's Disease Market Covering Sales Outlook, Up-to-date Key Trends, Market Size and Forecast, Per Capita Expenditure, Company Share, Brand Share, Regulations, Reimbursement Scenario, Epidemiology, Procedure Numbers, and Pipeline Assessment
An In-depth Market Insights of Parkinson's Disease Market including Juvenile Parkinson Disease, Young-Onset Parkinson’s Disease, and Idiopathic Parkinson Disease Covering 30+ Countries like United States, United Kingdom, Germany, France, Norway, Sweden, Saudi Arabia, United Arab Emirates, Japan, Korea, Australia, New Zealand, and Others
Parkinson's Disease Market Snapshot (2023 to 2033)
The global Parkinson's disease market is expected to be worth US$ 3.7 billion in the fiscal year 2023. From 2023 to 2033, the global market is expected to grow at a steady 5.1% CAGR, reaching a value of US$ 6.1 billion by the end of 2033.
Parkinson's disease is a disorder of the brain that results in the death of nerve cells in a particular region of the brain. It affects a person in many different ways, including stiffness, sadness, memory issues, problems with coordination and balance, blood pressure, and thinking. Despite the fact that the ailment cannot be cured, there are several treatment options, including surgery, medications, and other therapies.
The major treatment for Parkinson's is levodopa. Levodopa is frequently used with the drug carbidopa to combat its many negative effects, including nausea, vomiting, lower blood pressure, and restlessness. The size of the market for treatments for Parkinson's disease is expanding as a result of evolving environmental variables and genetic predisposition
The high prevalence of Parkinson's Condition (PD) in western nations, the growing senior population, who are all at high risk for acquiring the disease, and the robust pipeline of disease-modifying medicines are all expected to be key business drivers. The International Parkinson and Movement Disorder Society estimates that 9.4 million people will have PD globally in 2020. Additionally, about 1% of people over the age of 60 are affected by PD, and that percentage jumps to 5% for people over the age of 85.
Additionally, recent advances and strategic actions by large or minor market participants are growing in both local and international markets. This is yet another important feature that will amplify the industry under study. For instance, Israel-based Pharma Two B Ltd. announced in December 2021 that its Phase III double-blind, active-controlled study of P2B001 in early Parkinson's disease had successfully met its primary and important secondary endpoints. P2B001 was superior to each of its individual components as measured by the change in the total Unified Parkinson's Disease Rating Scale from baseline to week 12, which was the study's primary endpoint. P2B001 outperformed the pramipexole and rasagiline components, respectively, by 2.66 and 3.30 points, respectively (p=0.0018 and p=0.0001).
Attributes
Details
Expected Market Value (2023)
US$ 3.7 billion
Projected Forecast Value (2033)
US$ 6.1 billion
Global Growth Rate (2023 to 2033)
5.1%
CAGR of North America (2023)
12.5%
CAGR of APAC (2023 to 2033)
12%
Prominent Players in The Global Market
Merck & Co., Inc.
Mylan N.V.
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd.
Cipla Ltd.
Dr. Reddy's Laboratories Ltd.
Apotex Inc.
Sawai Pharmaceutical Co., Ltd.
Novartis
Zydus Cadila
Intas Pharmaceuticals Ltd.
Torrent Pharmaceuticals Ltd.
Amneal Pharmaceuticals
Aurobindo Pharma Limited
Lupin Limited
Glenmark Pharmaceuticals Ltd.
Alembic Pharmaceuticals Limited
Hikma Pharmaceuticals PLC
Lannett Company, Inc.
Accord Healthcare Ltd.
Morningside Pharmaceuticals Ltd.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2018 to 2022 Parkinson's Disease Market Demand Analysis Vs. Forecast 2023 to 2033
The global Parkinson's disease market grew at a CAGR of 6.8% from 2018 to 2022, as per Future Market Insights, a provider of market research and competitive intelligence. The Covid-19 pandemic has had a significant effect on the market. The COVID-19 pandemic has relatively little of an impact on the world market for Parkinson's disease medications. The epidemic has had a direct influence on the supply and demand for Parkinson's medications, as well as on businesses and financial markets. It has also disturbed the distribution system.
The gradual increase in PD prevalence has opened the door for major pharmaceutical companies to pursue significant market expansion in this industry. For pharmaceutical firms, the availability of several dosage forms might enable product diversification, resulting in higher profitability. For the treatment of people with moderate-to-severe PD for whom oral medicines are no longer effective, NeuroDerm is developing ND0612.
Such factors are expected to boost the global sales of Parkinson's disease solutions. As a result, the global Parkinson's disease market is expected to forecast a CAGR of over 5.1% from 2023-2033.
Continuous technological advances and research in this domain to boost the demand
Over the course of the analysis period, it is projected that ongoing developments in the Parkinson's disease drug category will drive market expansion. A research collaboration deal aimed at the discovery of novel biomolecular pre-clinical drug candidates for Parkinson's disease was signed in January 2022 by Iktos, a South Korean company that specializes in artificial intelligence (AI) for novel therapeutic design, and Astrogen, a medical and research-oriented biotech company aimed at developing new and innovative medications for the treatment of intractable neurodegenerative disorders.
Additionally, in March 2022, OrganoTherapeutics, a developer of patented technology patient-specific organoids that recapitulate Parkinson's Disease (PD) pathology, and Vyant Bio, Inc., an innovative biotechnology company concentrated on reinventing drug development for complex neurodevelopmental and neurodegenerative abnormalities, entered into a joint collaboration to work toward speeding up drug discovery. Such factors are sure to propel the market for Parkinson's disease during the forecast period.
Find your sweet spots for generating winning opportunities in this market.
The manufacturer's robust pipeline of pharmaceuticals will provide attractive prospects for the Parkinson's disease industry to flourish
New product introductions in the worldwide market for Parkinson's disease therapy will help the industry develop to its full potential. For example, Adamas Pharmaceuticals, Inc. revealed subgroup analyses of Parkinson's disease patients receiving amantadine immediate release (IR) who are still suffering dyskinesia and are recruited in the long-term EASE LID 2 trial in February 2018.
The current phase 3 open-label research of GOCOVRITM (amantadine) extended-release capsule data reveals that motor applications increase by roughly 35%. This patient's tolerability and safety profile were found to be consistent, with no side effects. Furthermore, the majority of the big companies have an extensive therapeutic pipeline for Parkinson's disease treatment. Such developments are expected to accelerate the demand for Parkinson's disease during the forecast period.
What Could Possibly Hinder Parkinson's Disease Market Demand?
Discovery of various alternative treatments to impede the global market
Alternative medical therapies will have a significant influence on the worldwide Parkinson's disease industry. Alternative treatment methods and alternative items will face fierce competition from companies producing the same medicine. This will make it difficult for the producer to expand and offer other products on the market for the same type of sickness.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Region-wise Analysis
What is the outlook of the North American Parkinson's disease market?
High prevalence among the aging population to boost the regional demand
North America is predicted to hold the dominant market share of 41% revenue share in 2023 and is the fastest-growing market for Parkinson's disease, with a dominant 12.1% CAGR from 2023 to 2033.
The factors that lead to regional expansion involve very prevalent Parkinson's disease groups. Furthermore, the high prevalence found in the aging population fuels the growth of the Parkinson's disease market in North America. In the United States, almost 1 Billion people have Parkinson's disease. According to Parkinson's Foundation figures, this amount is significantly more than the total number of persons diagnosed with multiple sclerosis as well as muscular dystrophy.
The overall direct and indirect expenses of Parkinson's disease, including treatment, social payments, and lost income, are estimated to be about US$ 52 billion per year in the United States alone. Furthermore, the Parkinson's Prevalence Project predicts that 930,000 persons in the United States will have Parkinson's disease (PD) by 2020. This figure is estimated to reach 1.2 Billion by the year 2030. Hence, there would be a lot of scope for North American manufacturers to develop in this market during the forecast period.
What can be expected from the APAC market for Parkinson's disease?
Large patient pool and more research and awareness programs to propel the sales
During the forecast period, the APAC market for Parkinson's disease is expected to garner a steady CAGR of 12%. But at the time, this market is presently acquiring 31% market share in the global Parkinson's disease market.
The emergence of a larger number of generic manufacturers as well as substantial market prospects for Parkinson's disease, notably in China, India, and Japan, will eventually drive the geographical expansion of the Asia-Pacific Parkinson's disease market.
The region is also seeing growth as a result of expanded product penetration, untapped potential, and the rising prevalence of Parkinson's disease in emerging nations. For example, UCB S.A. got an Import Drug License (IDL) from the China Food and Drug Administration (CFDA) in July 2022 to supply and distribute Neupro in China. Neupro is suggested as monotherapy in conjunction with levodopa for the treatment of people with early-stage idiopathic Parkinson's disease. Such developments are expected to accelerate the growth in the market from 2023 to 2033.
Category-wise Insights
Which drug class type segment is expected to gain traction from 2023 to 2033?
The Carbidopa-levodopa drug class segment will gain the dominant market share
Over the course of the forecast period, the Carbidopa-levodopa segment by drug class is anticipated to occupy a significant share of the global Parkinson's disease market. In 2023, this category is anticipated to dominate with a 32% revenue share.
The high incidence of these medications' prescriptions was thought to be the cause of this rise. According to the US Drug Use Statistics, 183,670 Parkinson's patients are expected to receive 527,540 prescriptions for carbidopa-levodopa in 2021.
Combinations of the drugs carbidopa along with levodopa are used to treat Parkinson's disease (PD) symptoms. It is the most effective drug for PD and is frequently used as a second line of therapy. It can be taken largely orally, for example, as immediate-release pills, controlled-release tablets, enteral solution, or extended-release capsules.
Additionally, the existence of pipeline candidates like LY03003 and an increase in the market for dopamine agonists are elements that are anticipated to favorably contribute to segmental growth. Such factors are expected to accelerate the growth prospects for Parkinson's disease from 2023 to 2033.
What would be the outlook of the age segment?
The adult segment will become more significant from 2023 to 2033
On the basis of the age type, the other dominant segment is the adult segment, which is expected to occupy a global market share of 21% from 2023 to 2033.
According to the journal article "Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease: Past, Present, and Future" released in February 2022, there are an estimated 6.1 Billion people worldwide who have Parkinson's disease. The prevalence rises with age, reaching from 1% to 3% in people over 65.
Additionally, UN research estimates that 727 Billion people worldwide would be 65 years of age or older in 2020. In addition, it is anticipated that by 2050, there will be twice as many people worldwide who are 80 years of age or older.
Additionally, according to figures released by the World Health Organization (WHO) in October 2021, 1 in 6 persons worldwide would be 60 years of age or older by the year 2030. Consequently, it is projected that there will be a demographic change as the world's geriatric population rises. The rise in older adults is anticipated to accelerate market growth over the study period.
Start-up Scenario
The start-ups want to differentiate their products on the worldwide market by adding new technology and improved safety features to their products. They are first concentrating on reducing the symptoms. Some of the businesses include:
The American company Skyhawk's Therapeutics is creating small-molecule therapeutics which correct RNA expression. Their unique approach makes it possible to create tiny compounds that target specific RNA splicing procedures. They are now working on drug options for neurological disorders, cancer, and other rare diseases.
Cala Health is a healthcare technology company that is pioneering a new form of electrical medicine known as neuro peripheral treatment. By using electronics placed on the body to externally stimulate peripheral nerves, neuro peripheral treatment offers the potential to treat chronic diseases. Experts from the fields of neurology, consumer electronics, as well as medical technologies are being brought together by Cala Health to provide affordable, non-invasive treatments for chronic diseases. Such treatments can be highly effective for the treatment of the symptoms of Parkinson's disease.
Competitive Landscape
Some of the prominent players in the global market for Parkinson's disease are:
Merck & Co., Inc.
Mylan N.V.
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd.
Cipla Ltd.
Dr. Reddy's Laboratories Ltd.
Apotex Inc.
Sawai Pharmaceutical Co., Ltd.
Novartis
Zydus Cadila
Intas Pharmaceuticals Ltd.
Torrent Pharmaceuticals Ltd.
Amneal Pharmaceuticals
Aurobindo Pharma Limited
Lupin Limited
Glenmark Pharmaceuticals Ltd.
Alembic Pharmaceuticals Limited
Hikma Pharmaceuticals PLC
Lannett Company, Inc.
Accord Healthcare Ltd.
Morningside Pharmaceuticals Ltd.
Some of the prominent developments of the key players in the market are:
Rusan Pharma announced the availability of a Parkinson's disease treatment in December 2018. The medicine 'Aposan' is used to monitor variations in Parkinson's disease patients who are not adequately managed by oral treatments currently available in the Indian market.
Biogen announced cooperation with Denali upon the LRRK2 program for Parkinson's disease and specific TV platform-enabled neurodegenerative disease initiatives in August 2020. They have agreed to collaborate on the development and commercialization of Denali's small-molecule inhibitors of leucine-rich repetitive kinase 2 (LRRK2) for Parkinson's disease. Biogen will also acquire the opportunity to opt into two projects and the first right of refusal for two more studies, all of which will be for neurodegenerative disorders that will use Denali's Transport Vehicle (TV) software company to breach the blood-brain barrier.
Value-added Insights:
Disease Epidemiology
Patient Treatment Journey
Product Adoption Analysis, By Region
New Product Launches and Approvals
Regulatory Scenario, By Key Countries
Reimbursement Scenario, By Key Countries
Porter’s Analysis
PESTLE Analysis
Market Entry Barriers
Supply Chain Assessment
Pipeline Assessment
By Phase
By Drug Class
By Company
Key Segments Covered In The Parkinson's Disease Market Report
By Drug Class:
Levodopa
50 mg levodopa combined with 12.5 mg carbidopa
100 mg levodopa combined with 25 mg carbidopa
100 mg levodopa combined with 10 mg carbidopa
200 mg levodopa combined with 50 mg carbidopa
250 mg levodopa combined with 25 mg carbidopa
At what rate did the Parkinson's disease market flourish from 2018 to 2022?
During the historical period of 2018 to 2022, the Parkinson's disease market grew at a CAGR of 6.8%.
What will be the growth rate of the global Parkinson's disease market during the forecast period?
The global Parkinson's disease market is predicted to rise with a steady 5.1% CAGR from 2023 to 2033.
What is the present market value of the Parkinson's disease market?
The global Parkinson's disease market is currently worth more than US$ 3.7 billion.
What will be the projected market size of the Parkinson's disease market by 2033?
By 2033, the global Parkinson's disease market is projected to reach a market size of US$ 6.1 billion.
Which segment is expected to dominate the global Parkinson's disease market during 2023?
In 2023, the Carbidopa-levodopa segment by drug class type is anticipated to dominate with a 32% revenue share.
What will be the outlook of the other segment during the forecast period?
The adult segment by age type will occupy the second largest segment during the forecast period with a 21% market share in 2023.
How is the North American Parkinson's disease market projected to grow during 2023 to 2033?
The North American region is predicted to grow with a steady CAGR of 12.5% from 2023 to 2033.
What is the outlook of the APAC Parkinson's disease market during 2023?
The APAC Parkinson's disease market is expected to grow with a steady CAGR of 12% from 2023 to 2033.
Table of Content
1. Executive Summary | Parkinson's Disease Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033
5.3.1. Juvenile Parkinson's Disease
5.3.2. Young-onset Parkinson’s Disease
5.3.3. Idiopathic Parkinson's Disease
5.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Age
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Age, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Age, 2023 to 2033
6.3.1. Adult
6.3.2. Pediatric
6.4. Y-o-Y Growth Trend Analysis By Age, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Age, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Diagnosis
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Diagnosis, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Diagnosis, 2023 to 2033
7.3.1. CT Scan
7.3.2. MRI Scan
7.3.3. DaTSCAN-SPECT scan
7.3.4. PET Scan
7.4. Y-o-Y Growth Trend Analysis By Diagnosis, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Diagnosis, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
8.3.1. Carbidopa-levodopa
8.3.2. Carbidopa-levodopa infusion
8.3.3. Dopamine Agonists
8.3.4. Monoamine Oxidase B Inhibitors
8.3.5. Catechol O-methyltransferase Inhibitors
8.3.6. Anticholinergics
8.3.7. Amantadine
8.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022
8.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
9.3.1. North America
9.3.2. Latin America
9.3.3. Western Europe
9.3.4. Eastern Europe
9.3.5. Asia-Pacific
9.3.6. Middle East & Africa (MEA)
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. The US
10.2.1.2. Canada
10.2.2. By Type
10.2.3. By Age
10.2.4. By Diagnosis
10.2.5. By Drug Class
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Type
10.3.3. By Age
10.3.4. By Diagnosis
10.3.5. By Drug Class
10.4. Key Takeaways
11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Type
11.2.3. By Age
11.2.4. By Diagnosis
11.2.5. By Drug Class
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Type
11.3.3. By Age
11.3.4. By Diagnosis
11.3.5. By Drug Class
11.4. Key Takeaways
12. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Benelux
12.2.1.2. France
12.2.1.3. Germany
12.2.1.4. Italy
12.2.1.5. Nordic
12.2.1.6. Spain
12.2.1.7. The UK
12.2.1.8. Rest of Western Europe
12.2.2. By Type
12.2.3. By Age
12.2.4. By Diagnosis
12.2.5. By Drug Class
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Type
12.3.3. By Age
12.3.4. By Diagnosis
12.3.5. By Drug Class
12.4. Key Takeaways
13. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. Poland
13.2.1.2. Russia
13.2.1.3. Rest of Eastern Europe
13.2.2. By Type
13.2.3. By Age
13.2.4. By Diagnosis
13.2.5. By Drug Class
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Type
13.3.3. By Age
13.3.4. By Diagnosis
13.3.5. By Drug Class
13.4. Key Takeaways
14. APAC Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. India
14.2.1.2. Malaysia
14.2.1.3. Singapore
14.2.1.4. Thailand
14.2.1.5. Australia
14.2.1.6. New Zealand
14.2.1.7. Rest of APAC
14.2.2. By Type
14.2.3. By Age
14.2.4. By Diagnosis
14.2.5. By Drug Class
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Type
14.3.3. By Age
14.3.4. By Diagnosis
14.3.5. By Drug Class
14.4. Key Takeaways
15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Type
15.2.3. By Age
15.2.4. By Diagnosis
15.2.5. By Drug Class
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Type
15.3.3. By Age
15.3.4. By Diagnosis
15.3.5. By Drug Class
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. The US
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Type
16.1.2.2. By Age
16.1.2.3. By Diagnosis
16.1.2.4. By Drug Class
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Type
16.2.2.2. By Age
16.2.2.3. By Diagnosis
16.2.2.4. By Drug Class
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Type
16.3.2.2. By Age
16.3.2.3. By Diagnosis
16.3.2.4. By Drug Class
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Type
16.4.2.2. By Age
16.4.2.3. By Diagnosis
16.4.2.4. By Drug Class
16.5. Benelux
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Type
16.5.2.2. By Age
16.5.2.3. By Diagnosis
16.5.2.4. By Drug Class
16.6. France
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Type
16.6.2.2. By Age
16.6.2.3. By Diagnosis
16.6.2.4. By Drug Class
16.7. Germany
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Type
16.7.2.2. By Age
16.7.2.3. By Diagnosis
16.7.2.4. By Drug Class
16.8. Italy
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Type
16.8.2.2. By Age
16.8.2.3. By Diagnosis
16.8.2.4. By Drug Class
16.9. Nordic
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Type
16.9.2.2. By Age
16.9.2.3. By Diagnosis
16.9.2.4. By Drug Class
16.10. Spain
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Type
16.10.2.2. By Age
16.10.2.3. By Diagnosis
16.10.2.4. By Drug Class
16.11. The UK
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Type
16.11.2.2. By Age
16.11.2.3. By Diagnosis
16.11.2.4. By Drug Class
16.12. Poland
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Type
16.12.2.2. By Age
16.12.2.3. By Diagnosis
16.12.2.4. By Drug Class
16.13. Russia
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Type
16.13.2.2. By Age
16.13.2.3. By Diagnosis
16.13.2.4. By Drug Class
16.14. India
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Type
16.14.2.2. By Age
16.14.2.3. By Diagnosis
16.14.2.4. By Drug Class
16.15. Malaysia
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Type
16.15.2.2. By Age
16.15.2.3. By Diagnosis
16.15.2.4. By Drug Class
16.16. Singapore
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Type
16.16.2.2. By Age
16.16.2.3. By Diagnosis
16.16.2.4. By Drug Class
16.17. Thailand
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Type
16.17.2.2. By Age
16.17.2.3. By Diagnosis
16.17.2.4. By Drug Class
16.18. Australia
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Type
16.18.2.2. By Age
16.18.2.3. By Diagnosis
16.18.2.4. By Drug Class
16.19. New Zealand
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Type
16.19.2.2. By Age
16.19.2.3. By Diagnosis
16.19.2.4. By Drug Class
16.20. GCC Countries
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Type
16.20.2.2. By Age
16.20.2.3. By Diagnosis
16.20.2.4. By Drug Class
16.21. South Africa
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Type
16.21.2.2. By Age
16.21.2.3. By Diagnosis
16.21.2.4. By Drug Class
16.22. Israel
16.22.1. Pricing Analysis
16.22.2. Market Share Analysis, 2022
16.22.2.1. By Type
16.22.2.2. By Age
16.22.2.3. By Diagnosis
16.22.2.4. By Drug Class
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Type
17.3.3. By Age
17.3.4. By Diagnosis
17.3.5. By Drug Class
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Sunovion Pharmaceuticals
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. Adamas Pharmaceuticals
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. Neurocrine Biosciences
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. Supernus Pharmaceuticals
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. Kyowa Kirin
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. AbbVie
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. Integrative Research Laboratories AB
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. Annovis Bio Inc.
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. Cerevel Therapeutics
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. AMillioneal Pharmaceuticals
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
19. Assumptions & Acronyms Used20. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Age, 2018 to 2033
Table 4: Global Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 5: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 7: North America Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 8: North America Market Value (US$ Million) Forecast by Age, 2018 to 2033
Table 9: North America Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 10: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 11: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 12: Latin America Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 13: Latin America Market Value (US$ Million) Forecast by Age, 2018 to 2033
Table 14: Latin America Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 15: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 16: Western Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 17: Western Europe Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 18: Western Europe Market Value (US$ Million) Forecast by Age, 2018 to 2033
Table 19: Western Europe Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 20: Western Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 21: Eastern Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: Eastern Europe Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 23: Eastern Europe Market Value (US$ Million) Forecast by Age, 2018 to 2033
Table 24: Eastern Europe Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 25: Eastern Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 26: APAC Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 27: APAC Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 28: APAC Market Value (US$ Million) Forecast by Age, 2018 to 2033
Table 29: APAC Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 30: APAC Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 31: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 32: MEA Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 33: MEA Market Value (US$ Million) Forecast by Age, 2018 to 2033
Table 34: MEA Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 35: MEA Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Type, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Age, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 4: Global Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 5: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 6: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 7: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 8: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 9: Global Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 10: Global Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 11: Global Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 12: Global Market Value (US$ Million) Analysis by Age, 2018 to 2033
Figure 13: Global Market Value Share (%) and BPS Analysis by Age, 2023 to 2033
Figure 14: Global Market Y-o-Y Growth (%) Projections by Age, 2023 to 2033
Figure 15: Global Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 16: Global Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 17: Global Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 18: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 19: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 20: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 21: Global Market Attractiveness by Type, 2023 to 2033
Figure 22: Global Market Attractiveness by Age, 2023 to 2033
Figure 23: Global Market Attractiveness by Diagnosis, 2023 to 2033
Figure 24: Global Market Attractiveness by Drug Class, 2023 to 2033
Figure 25: Global Market Attractiveness by Region, 2023 to 2033
Figure 26: North America Market Value (US$ Million) by Type, 2023 to 2033
Figure 27: North America Market Value (US$ Million) by Age, 2023 to 2033
Figure 28: North America Market Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 29: North America Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 30: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 31: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 34: North America Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 35: North America Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 37: North America Market Value (US$ Million) Analysis by Age, 2018 to 2033
Figure 38: North America Market Value Share (%) and BPS Analysis by Age, 2023 to 2033
Figure 39: North America Market Y-o-Y Growth (%) Projections by Age, 2023 to 2033
Figure 40: North America Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 41: North America Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 42: North America Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 43: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 44: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 45: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 46: North America Market Attractiveness by Type, 2023 to 2033
Figure 47: North America Market Attractiveness by Age, 2023 to 2033
Figure 48: North America Market Attractiveness by Diagnosis, 2023 to 2033
Figure 49: North America Market Attractiveness by Drug Class, 2023 to 2033
Figure 50: North America Market Attractiveness by Country, 2023 to 2033
Figure 51: Latin America Market Value (US$ Million) by Type, 2023 to 2033
Figure 52: Latin America Market Value (US$ Million) by Age, 2023 to 2033
Figure 53: Latin America Market Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 54: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 55: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 56: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 57: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 58: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 59: Latin America Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 60: Latin America Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 61: Latin America Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 62: Latin America Market Value (US$ Million) Analysis by Age, 2018 to 2033
Figure 63: Latin America Market Value Share (%) and BPS Analysis by Age, 2023 to 2033
Figure 64: Latin America Market Y-o-Y Growth (%) Projections by Age, 2023 to 2033
Figure 65: Latin America Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 66: Latin America Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 67: Latin America Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 68: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 69: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 70: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 71: Latin America Market Attractiveness by Type, 2023 to 2033
Figure 72: Latin America Market Attractiveness by Age, 2023 to 2033
Figure 73: Latin America Market Attractiveness by Diagnosis, 2023 to 2033
Figure 74: Latin America Market Attractiveness by Drug Class, 2023 to 2033
Figure 75: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 76: Western Europe Market Value (US$ Million) by Type, 2023 to 2033
Figure 77: Western Europe Market Value (US$ Million) by Age, 2023 to 2033
Figure 78: Western Europe Market Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 79: Western Europe Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 80: Western Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 81: Western Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 82: Western Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 83: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 84: Western Europe Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 85: Western Europe Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 86: Western Europe Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 87: Western Europe Market Value (US$ Million) Analysis by Age, 2018 to 2033
Figure 88: Western Europe Market Value Share (%) and BPS Analysis by Age, 2023 to 2033
Figure 89: Western Europe Market Y-o-Y Growth (%) Projections by Age, 2023 to 2033
Figure 90: Western Europe Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 91: Western Europe Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 92: Western Europe Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 93: Western Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 94: Western Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 95: Western Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 96: Western Europe Market Attractiveness by Type, 2023 to 2033
Figure 97: Western Europe Market Attractiveness by Age, 2023 to 2033
Figure 98: Western Europe Market Attractiveness by Diagnosis, 2023 to 2033
Figure 99: Western Europe Market Attractiveness by Drug Class, 2023 to 2033
Figure 100: Western Europe Market Attractiveness by Country, 2023 to 2033
Figure 101: Eastern Europe Market Value (US$ Million) by Type, 2023 to 2033
Figure 102: Eastern Europe Market Value (US$ Million) by Age, 2023 to 2033
Figure 103: Eastern Europe Market Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 104: Eastern Europe Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 105: Eastern Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 106: Eastern Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 107: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 108: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 109: Eastern Europe Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 110: Eastern Europe Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 111: Eastern Europe Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 112: Eastern Europe Market Value (US$ Million) Analysis by Age, 2018 to 2033
Figure 113: Eastern Europe Market Value Share (%) and BPS Analysis by Age, 2023 to 2033
Figure 114: Eastern Europe Market Y-o-Y Growth (%) Projections by Age, 2023 to 2033
Figure 115: Eastern Europe Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 116: Eastern Europe Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 117: Eastern Europe Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 118: Eastern Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 119: Eastern Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 120: Eastern Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 121: Eastern Europe Market Attractiveness by Type, 2023 to 2033
Figure 122: Eastern Europe Market Attractiveness by Age, 2023 to 2033
Figure 123: Eastern Europe Market Attractiveness by Diagnosis, 2023 to 2033
Figure 124: Eastern Europe Market Attractiveness by Drug Class, 2023 to 2033
Figure 125: Eastern Europe Market Attractiveness by Country, 2023 to 2033
Figure 126: APAC Market Value (US$ Million) by Type, 2023 to 2033
Figure 127: APAC Market Value (US$ Million) by Age, 2023 to 2033
Figure 128: APAC Market Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 129: APAC Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 130: APAC Market Value (US$ Million) by Country, 2023 to 2033
Figure 131: APAC Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 132: APAC Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 133: APAC Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 134: APAC Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 135: APAC Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 136: APAC Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 137: APAC Market Value (US$ Million) Analysis by Age, 2018 to 2033
Figure 138: APAC Market Value Share (%) and BPS Analysis by Age, 2023 to 2033
Figure 139: APAC Market Y-o-Y Growth (%) Projections by Age, 2023 to 2033
Figure 140: APAC Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 141: APAC Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 142: APAC Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 143: APAC Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 144: APAC Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 145: APAC Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 146: APAC Market Attractiveness by Type, 2023 to 2033
Figure 147: APAC Market Attractiveness by Age, 2023 to 2033
Figure 148: APAC Market Attractiveness by Diagnosis, 2023 to 2033
Figure 149: APAC Market Attractiveness by Drug Class, 2023 to 2033
Figure 150: APAC Market Attractiveness by Country, 2023 to 2033
Figure 151: MEA Market Value (US$ Million) by Type, 2023 to 2033
Figure 152: MEA Market Value (US$ Million) by Age, 2023 to 2033
Figure 153: MEA Market Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 154: MEA Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 155: MEA Market Value (US$ Million) by Country, 2023 to 2033
Figure 156: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 157: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 158: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 159: MEA Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 160: MEA Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 161: MEA Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 162: MEA Market Value (US$ Million) Analysis by Age, 2018 to 2033
Figure 163: MEA Market Value Share (%) and BPS Analysis by Age, 2023 to 2033
Figure 164: MEA Market Y-o-Y Growth (%) Projections by Age, 2023 to 2033
Figure 165: MEA Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 166: MEA Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 167: MEA Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 168: MEA Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 169: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 170: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 171: MEA Market Attractiveness by Type, 2023 to 2033
Figure 172: MEA Market Attractiveness by Age, 2023 to 2033
Figure 173: MEA Market Attractiveness by Diagnosis, 2023 to 2033
Figure 174: MEA Market Attractiveness by Drug Class, 2023 to 2033
Figure 175: MEA Market Attractiveness by Country, 2023 to 2033
